首页> 外文期刊>Neuropsychiatric Disease and Treatment >Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database
【24h】

Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database

机译:抗精神病药物治疗中受体 - 亲和力概况的再生长风险:使用日本就业的健康保险数据库的倾向得分匹配分析

获取原文
           

摘要

Purpose:The aim of this study was to examine whether there is a difference in the risk of rehospitalization when antipsychotics are classified into two groups treated using drugs with a higher or lower affinity to H1 or α1 receptors than to D2 receptors (histamine H1 receptors, adrenaline α1 receptors [HA] high- and HA low-affinity drug group, respectively) based on affinity to receptors related to sedation using a nationwide insurance claims database in Japan.Patients and Methods:We identified eligible patients by the following two criteria: (i) hospitalization due to schizophrenia (International Classification of Disease [ICD]-10 code: F20 or F25) in psychiatric wards between January 1st, 2005 and August 31st, 2017, and (ii) administration of HA high- or HA low-affinity drugs in the next month after discharge from the earliest hospitalization due to schizophrenia (index month). The primary endpoint was rehospitalization due to schizophrenia. The secondary endpoints were (i) involuntary rehospitalization, (ii) concomitant use of anxiolytics/hypnotics, mood stabilizers, and antiparkinsonian drugs, (iii) all-cause death, and (iv) medication discontinuation. Propensity score (PS) matching analysis was applied, and the hazard ratio (HR) of the event rate in the HA high-affinity drug group relative to the HA low-affinity drug group was calculated using Cox's proportional hazards model.Results:Two thousand nine hundred and forty patients were identified as eligible patients. Among PS-matched patients (819 in each group), the HR in the HA high-affinity drug group compared with the HA low-affinity drug group was 1.018 (0.822-1.260, P = 0.870). Other outcomes did not differ significantly between the two groups.Conclusion:No significant difference was observed in the rehospitalization risk due to schizophrenia associated with HA high-affinity antipsychotic drugs. Although this study was a retrospective PS-matched cohort study, the possibility of masking of the rehospitalization risk cannot be excluded because more than 80% of the patients were administered an anxiolytic/hypnotic at the time of admission.? 2020 Takekita et al.
机译:目的:本研究的目的是检查抗精神病药分类为使用具有较高或α1受体的药物治疗的两组抗精神来发的再生风险是否存在差异,而不是D2受体(组胺H1受体,肾上腺素α1受体[HA]高和HA低亲和药物药物,基于在日本的全国保险索赔数据库使用全国保险索赔数据库的对受体的亲和力.Patient和方法:我们通过以下两个标准确定了合格的患者:( i)由于​​精神分裂症因精神分裂症(国际疾病分类 - 10码:F20或F25),在2005年1月1日至2017年8月31日至2017年8月31日之间的精神病病房和(ii)HA高或HA低亲和力从精神分裂症(指数月份)的最早住院后,下个月的药物。由于精神分裂症,主要终点是重新生长化。次要终点是(i)非自愿再生长,(ii)伴随着使用抗焦虑/催眠药,情绪稳定剂和抗磷酸糖尿药物,(iii)全因死亡,(iv)药物停止。使用Cox的比例危险模型计算倾向评分(PS)匹配分析,HA高亲和力药物组中HA高亲和力药物组的事件率的危险比(HR)进行计算。结果:两千九百患者被鉴定为符合条件的患者。在PS匹配的患者(每组819中),HA高亲和力药物组中的HR与HA低亲和力药物组为1.018(0.822-1.260,P = 0.870)。两组之间的其他结果没有显着差异。结论:由于与HA高亲和力抗精神病药相关的精神分裂症,在再生生殖风险中没有观察到显着差异。虽然这项研究是一个回顾性PS匹配的队列研究,但不能排除掩盖再生活风险的可能性,因为超过80%的患者在入院时施用抗焦虑/催眠。 2020 Takekita等人。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号